Welcome to our dedicated page for Biophytis SA American Depositary Share (0.01 Euro) news (Ticker: BPTS), a resource for investors and traders seeking the latest updates and insights on Biophytis SA American Depositary Share (0.01 Euro) stock.
Biophytis SA (Symbol: BPTS) is a clinical-stage biotechnology company dedicated to developing drug candidates for age-related diseases. Founded in 2006 as a spin-off from Université Pierre et Marie Curie (Paris), Biophytis focuses on addressing conditions that become increasingly prevalent with aging, such as sarcopenia, dry age-related macular degeneration, and COVID-19-related respiratory issues.
The company's leading drug candidate, Ruvembri™ (20-hydroxyecdysone), has shown promising results in clinical trials. It is currently being evaluated in several rigorous studies, including the phase 3 SARA-31 study for sarcopenia and a phase 2-3 study for severe COVID-19. The SARA-INT phase 2 study demonstrated notable improvements in physical performance, evidenced by the 400 Meter Walking Test results.
Biophytis has also recently initiated the OBA clinical program, which aims to explore the efficacy of BIO101 (20-hydroxyecdysone) in treating obesity, especially in patients who are also being treated with GLP-1 receptor agonists. This program addresses the often-overlooked issue of muscle loss during obesity treatment, aiming to preserve muscle function while facilitating weight loss.
The company operates out of Paris, France, and Cambridge, Massachusetts, and is actively seeking partnerships to further develop and market its drug candidates. Biophytis' American Depositary Shares (ADS) are traded on the Nasdaq Capital Market under the ticker BPTS, while its ordinary shares are listed on Euronext Growth Paris under the ticker ALBPS.
In terms of financial health, Biophytis has successfully secured financing to sustain its activities until early 2025, despite a challenging financial environment for the biotech sector. This stable financial footing allows the company to continue its innovative work and expand its clinical programs.
Stay updated with the latest from Biophytis, including their groundbreaking research and strategic developments, by visiting their official website.
FAQ
What is the current stock price of Biophytis SA American Depositary Share (0.01 Euro) (BPTS)?
What is the market cap of Biophytis SA American Depositary Share (0.01 Euro) (BPTS)?
What is Biophytis SA specialized in?
What is RuvembriTM?
Where is Biophytis SA located?
What recent achievements has Biophytis made?
How is Biophytis funded?
What is the SARA-INT study?
What stock markets are Biophytis' shares listed on?
What is the focus of the OBA clinical program?
What is Biophytis' financial outlook?
How can I stay updated on Biophytis' developments?
